CTTI Publication Investigates Organizational Practices to Promote Diversity and Inclusion in Clinical Trials

A new CTTI publication, published in the Journal of Clinical Pharmacology & Therapeutics, investigates organizational-level practices for enhancing diversity and inclusion in clinical trials as one component of advancing health equity and improving health outcomes. When clinical trial participants do not reflect the populations that will use the medical product, it can limit our understanding of the safety and efficacy of the investigational medical product, restrict the availability of evidence-based treatment guidelines for vulnerable populations disproportionally burdened by disease, and delay access to innovative and potentially life-extending therapies.  

CTTI interviewed 36 senior-level leaders at 20 organizations that conduct clinical trials to gather perspectives on strategies to support diversity and inclusion in clinical research. Based on these interviews and a 2-day meeting with 53 experts, CTTI identified four key action areas to implement sustainable, organizational-level practices: commitment, partnerships, accountability, and resources. To improve equitable access and increase diversity in clinical trial populations, CTTI suggests making diversity and inclusion in clinical trials an organizational priority and defining responsibility for these efforts, establishing and maintaining bi-directional community partnerships, and allocating organizational resources that support diversity and inclusion in clinical research. The CTTI Diversity Project Team is using the findings from this research to develop recommendations and a tool for institutions to use to initiate or enhance their diversity and inclusion efforts. 

CTTI Holds Meeting to Discuss the Systemic Changes Needed to Increase Diversity in Clinical Trials

The Clinical Trials Transformation Initiative (CTTI) held a two-day multi-stakeholder expert meeting on Oct. 12 & 21 to discuss the systemic changes needed to ensure that U.S. clinical trials better meet the needs of diverse populations, including racial minorities, ethnic minorities, and women. At the meeting, leaders and key stakeholders from across the clinical trials ecosystem participated in an engaging forum, informative discussions, and lively breakout sessions that shed more light on new solutions for sharing information and ensuring sufficient resource allocation to diversity, equity, and inclusion initiatives.

Meeting attendees also identified some important themes and identified opportunities to increase diversity in clinical trials:

  • The benefits are indisputable. Including a diverse population in clinical trials improves the quality of science, enhances patient trust, increases patient recruitment and retention, and improves clinical care for all patients.
  • A culture shift is needed. Organizations need to ingrain diversity, equity, and inclusion initiatives into their portfolio-level strategy and within their overall mission. They should foster bi-directional community partnerships and directly engage patients in the design and planning of clinical trials and diversity efforts from the very beginning.
  • This is a full group effort. Increasing diversity in clinical trials is a multi-stakeholder effort that will take all groups working together to achieve goals of clinical trial populations representing the populations who are affected by disease.
  • There is important work ahead of us. Meeting attendees provided feedback on CTTI’s draft maturity model, helping to create a better public resource. Suggested additions included a focus on values and guidelines that are generalizable to a wide variety of stakeholders, not just industry stakeholders, and more guidance on how organizations can measure their progress through the maturity model.

CTTI is now using these findings – along with other research results and multi-stakeholder discussions – to develop recommendations and resources for release in early 2022. The project team may host additional webinars focusing on case studies and implementation of resources.

Clinical Trials Issues Related to COVID-19

Topics Included: Access to Clinical Trials, Ensuring Quality, Innovative Trials, Regulatory Submissions + Approvals

Overview

The COVID-19 pandemic caused unprecedented disruptions to nearly every aspect of clinical research.

To help, CTTI led several efforts -- including conducting surveys, holding webinars, and developing resources -- with the goal of helping the clinical trials ecosystem adapt and move forward during the pandemic, including:

Resources

Patient Engagement | Resources

Diversity Maturity Model for Organizational-Level Strategies

Diversity Maturity Model for Organizational-Level Strategies

Patient Engagement | Recommendations

Increasing Diversity in Clinical Trials

Increasing Diversity in Clinical Trials

Access to Clinical Trials | CTTI News

CTTI Publication Investigates Organizational Practices to Promote Diversity and Inclusion in Clinical Trials

A new CTTI publication, published in the Journal of Clinical Pharmacology & Therapeutics, investigates organizational-level practices for enhancing diversity and inclusion in clinical trials as one component of advancing health...

Patient Engagement | Publications

Enhancing Diversity and Inclusion in Clinical Trials

Women and people from most racial and ethnic groups in the United States have historically been under-represented in clinical trials of investigational medical products. Inadequate representation of these groups may...

Site Planning | Case Studies

Accelerating eConsent Adoption During COVID-19

Accelerating eConsent Adoption During COVID-19

Access to Clinical Trials | CTTI News

CTTI Holds Meeting to Discuss the Systemic Changes Needed to Increase Diversity in Clinical Trials

The Clinical Trials Transformation Initiative (CTTI) held a two-day multi-stakeholder expert meeting on Oct. 12 & 21 to discuss the systemic changes needed to ensure that U.S. clinical trials better...

Patient Engagement | Resources

Advancing the Landscape: Increasing Diversity in Clinical Trials

Advancing the Landscape: Increasing Diversity in Clinical Trials

Regulatory Submissions + Approvals | Resources

Best Practices for Designing High-Quality, Diverse COVID-19 Trials

Collating insights from across the clinical trials ecosystem, the Clinical Trials Transformation Initiative (CTTI) identified eight best practices for designing and conducting COVID-19 treatment clinical trials.

Regulatory Submissions + Approvals | Resources

Best Practices for Conducting Trials during the COVID-19 Pandemic

This document details the findings from CTTI’s surveys on ongoing trials during COVID-19 and expands on points highlighted during those corresponding webinars.

Regulatory Submissions + Approvals

Clinical Trials Issues Related to COVID-19

The COVID-19 pandemic turned our world upside down. And, within the clinical trials community, nearly every aspect of research experienced unprecedented disruptions.

Formats

Stage of Trial